Euroapi has updated its outlook for 2024, to reflect a divestment of the Haverhill and Brindisi production sites now scheduled before the end of 2027, as part of the rationalization of its industrial footprint.

The Group now anticipates between 8 and 11% decline in sales in 2024 compared with 2023 on a comparable basis, with second-half performance expected to exceed that of the first half, and between 4 and 7% Core EBITDA margin.

Euroapi also reports that it has reached an agreement with its former parent company Sanofi on the financing of the Focus-27 plan, following ongoing discussions with banks to amend and extend the current RCF credit agreement.

Through its Focus-27 plan, it is targeting 75 to 80 million euros of additional Core EBITDA per year by the end of 2027, 'thanks to a higher value-added API and CDMO offering, a streamlined industrial footprint and significant cost reductions'.

Copyright (c) 2024 CercleFinance.com. All rights reserved.